Alexander Eggermont

31.9k citations

218 papers · 11.9k indexed · 2 hit papers · h-index 59

Impact in

Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in

Immunology 110
- Immunotherapy and Immune Responses 76
- Immune Cell Function and Interaction 39
- T-cell and B-cell Immunology 16
Oncology 115
- Cancer Immunotherapy and Biomarkers 49
- CAR-T cell therapy research 47
- Cutaneous Melanoma Detection and Management 22

Co-authors: Laurence Zitvogel Guido Kroemer Lorenzo Galluzzi Jérôme Galon Erika Vacchelli Timo L.M. ten Hagen Catherine Sautès‐Fridman Éric Tartour
Journals: OncoImmunology (49 papers)European Journal of Cancer (17 papers)Journal of Clinical Oncology (9 papers)International Journal of Cancer (8 papers)Annals of Oncology (8 papers)
Partner nations: Netherlands France Belgium

In The Last Decade

Alexander Eggermont

217 papers receiving 11.7k citations

Hit Papers

align trajectories log scale

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy 2016 · 976 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Annals of Oncology
2016 Journal of Clinical Investigation

Peers

Countries citing papers authored by Alexander Eggermont

Since Specialization

Citations

This map shows the geographic impact of Alexander Eggermont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Eggermont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Eggermont more than expected).

Fields of papers citing papers by Alexander Eggermont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Eggermont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Eggermont. The network helps show where Alexander Eggermont may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alexander Eggermont, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alexander Eggermont Line = papers co-authored together Alexander Eggermont links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Role of CDCA2 in tumor genesis, prognosis and future treatments European Journal of Cancer ·Xinyi Lin, Rasmus Grønfeldt Winther, B.K. Shoichet, Tong Wang, Wenjie Ma, Connor Hyland, Wei Sun, Yu Xu, Alexander Eggermont, Yong Chen	2024	2
2	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours Nature Communications ·Aurélie Durgeau, Yasemin Virk, Gwendoline Gros, Zhidan Wen, Stéphanie Corgnac, K. А. Zhusupova, Jérôme Salmon, Julien Adam, Vincent de Montpréville, Pierre Validire, Soldano Ferrone, Salem Chouaı̈b, Alexander Eggermont, Jean‐Charles Soria, François A. Lemonnier, Éric Tartour, Nathalie Chaput, Benjamin Besse, Fathia Mami‐Chouaib	2018	21
3	Dendritic cell–derived exosomes for cancer therapy Journal of Clinical Investigation ·Jonathan M. Pitt, Fabrice André, Sebastián Amigorena, Jean‐Charles Soria, Alexander Eggermont, Guido Kroemer, Laurence Zitvogel Hit paper breakdown →	2016	507
4	Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers ESMO Open ·Josep Tabernero, Malvika Vyas, Rosa Giuliani, Dirk Arnold, Fátima Cardoso, Paolo G. Casali, Andrés Cervantes, Alexander Eggermont, Alexandru Eniu, Jacek Jassem, George Pentheroudakis, Solange Peters, Stefan Rauh, Christoph Zielinski, Rolf A. Stahel, Emile E. Voest, Jean-Yves Douillard, Keith McGregor, Fortunato Ciardiello	2016	88
5	Trial watch: Naked and vectored DNA-based anticancer vaccines OncoImmunology ·Norma Bloy, Aitziber Buqué, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Catherine Sautès‐Fridman, Jitka Fučíková, Jérôme Galon, Radek Špíšek, Éric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2015	32
6	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications OncoImmunology ·Erika Vacchelli, Jonathan Pol, Norma Bloy, Alexander Eggermont, Isabelle Cremer, Wolf H. Fridman, Jérôme Galon, Aurélien Marabelle, Holbrook E. Kohrt, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2015	40
7	Trial Watch—Immunostimulation with cytokines in cancer therapy OncoImmunology ·Erika Vacchelli, Fernando Aranda, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf H. Fridman, Jitka Fučíková, Jérôme Galon, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2015	44
8	Trial Watch: Radioimmunotherapy for oncological indications OncoImmunology ·Norma Bloy, Jonathan Pol, Gwenola Manic, Ilio Vitale, Alexander Eggermont, Jérôme Galon, Éric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2014	47
9	Trial watch: IDO inhibitors in cancer therapy OncoImmunology ·Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Catherine Sautès‐Fridman, Éric Tartour, Eugene P. Kennedy, Michael Platten, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2014	288
10	Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab Cancer Research ·Diane Goèré, Caroline Flament, Sylvie Rusakiewicz, Vichnou Poirier-Colame, Oliver Kepp, Isabelle Martins, Talita Sabino Fanticelli Moreira, Alexander Eggermont, Dominique Elias, Nathalie Chaput, Laurence Zitvogel	2013	34
11	Immunotherapy and the concept of a clinical cure European Journal of Cancer ·Alexander Eggermont, Guido Kroemer, Laurence Zitvogel	2013	38
12	Trial watch OncoImmunology ·Laurie Menger, Erika Vacchelli, Oliver Kepp, Alexander Eggermont, Éric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2013	108
13	Trial Watch: Lenalidomide-based immunochemotherapy OncoImmunology ·Michaëla Semeraro, Erika Vacchelli, Alexander Eggermont, Jérôme Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi	2013	53
14	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy OncoImmunology ·Erika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, Wolf H. Fridman, Jérôme Galon, Catherine Sautès‐Fridman, Éric Tartour, Laurence Zitvogel, Guido Kroemer	2012	199
15	Bcl-2 associated anthanogen-1 (Bag-1) expression and prognostic value in pancreatic head and periampullary cancer European Journal of Cancer ·Matthew A. Schulz, Timo L.M. ten Hagen, Wim C.J. Hop, Herman van Dekken, Bilyana M. Dicheva, Ann L.B. Seynhaeve, Gerben A. Koning, Alexander Eggermont, Casper H.J. van Eijck	2012	4
16	Immunostimulation Versus Immunosuppression after Multiple Vaccinations: the Woes of Therapeutic Vaccine Development Clinical Cancer Research ·Alexander Eggermont	2009	25
17	Tumor Necrosis Factor α Mediates Homogeneous Distribution of Liposomes in Murine Melanoma that Contributes to a Better Tumor Response Cancer Research ·Ann L.B. Seynhaeve, Saske Hoving, Debby Schipper, Chunling Li, 郭启海, Sandra T. van Tiel, Alexander Eggermont, Timo L.M. ten Hagen	2007	142
18	Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein The Journal of Immunology ·Yi Zhang, Zhaojun Sun, Hugues J. M. Nicolay, Ralf G. Meyer, Nicolina Renkvist, Vincent Stroobant, Jurgen Corthals, Javier Carrasco, Alexander Eggermont, Marie Marchand, Kris Thielemans, Thomas Wölfel, Thierry Boon, Pierre van der Bruggen	2005	26
19	A MAGE-3 Peptide Presented by HLA-DR1 to CD4+ T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein The Journal of Immunology ·Yi Zhang, Pascal Chaux, Vincent Stroobant, Alexander Eggermont, Jurgen Corthals, Bernard Maillère, Kris Thielemans, Marie Marchand, Thierry Boon, Pierre van der Bruggen	2003	35
20	Twenty-five years of pluridisciplinary approach for melanoma patients. The European Organization on Research and Treatment of Cancer Melanoma Cooperative Group (EORTC???MCG) Melanoma Research ·문숙영, Alexander Eggermont	1995	5

About Alexander Eggermont

Alexander Eggermont is a scholar working on Immunology, Oncology, Biological Psychiatry, Immunology and Allergy and Biomaterials, having authored 218 papers that have together received 11.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (76 papers), Cancer Immunotherapy and Biomarkers (49 papers), CAR-T cell therapy research (47 papers), Immune Cell Function and Interaction (39 papers), Cutaneous Melanoma Detection and Management (22 papers), Nanoparticle-Based Drug Delivery (22 papers), Melanoma and MAPK Pathways (19 papers) and T-cell and B-cell Immunology (16 papers). The work is most often cited by research in Immunology (5.3k citations), Oncology (5.7k citations), Cancer Research (1.4k citations), Biological Psychiatry (213 citations) and Biomaterials (1.0k citations). Alexander Eggermont has collaborated with scholars based in Netherlands, France and Belgium. Frequent co-authors include Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Jérôme Galon, Erika Vacchelli, Timo L.M. ten Hagen, Catherine Sautès‐Fridman, Éric Tartour, Jonathan M. Pitt and Wolf H. Fridman. Their work appears in journals such as OncoImmunology, European Journal of Cancer, Journal of Clinical Oncology, International Journal of Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact